The Beijing Municipal Intellectual Property Office organized the 2024 application and review for Beijing Intellectual Property Pilot and Advantageous Units in accordance with the Measures for the Identification and Management of Beijing Intellectual Property Pilot and Advantageous Units (Jingzhiju [2024] No. 130){insert\_element\_0\_}. Following preliminary review, verification, and evaluation, 199 entities were designated as 2024 Beijing Intellectual Property Advantageous Units. Rocgene (Beijing) Scientific Instruments Co., Ltd. is honored to be among them.

Rocgene has long been committed to translating cutting-edge life science research technologies into clinically relevant medical research products and developing proprietary research and molecular diagnostic products with independent intellectual property rights. Through sustained R&D investment and recruitment of top domestic and international talent, the company has established a comprehensive R&D and innovation system. To date, Rocgene holds 67 patents, including 41 invention patents, 12 utility model patents, and 14 design patents, as well as 47 software copyrights. Backed by continuous scientific innovation, Rocgene has developed a complete gene detection solution, with products exported to nearly 20 countries worldwide.

Previously, Rocgene has been honored with titles including National High-Tech Enterprise, Beijing Specialized, Refined, Differential, and Innovative (SRDI) Small and Medium Enterprise, and Zhongguancun High-Tech Enterprise. Being selected as a Beijing Intellectual Property Advantageous Unit will further motivate Rocgene to uphold an innovation-driven development philosophy, persist in independent R&D, and continue investing in research to contribute to the advancement of the in vitro diagnostics industry.

About Rocgene

Founded in 2016, Rocgene (Beijing) Scientific Instruments Co., Ltd. (Rocgene) is a high-tech biotech company established by scientists and business professionals and driven by core technologies. Rocgene is dedicated to translating cutting-edge life science research into clinically relevant medical research products and developing proprietary research and molecular diagnostic products with independent intellectual property rights.

Rocgene has been awarded numerous honors, including National High-Tech Enterprise, Beijing SRDI Small and Medium Enterprise, and Zhongguancun High-Tech Enterprise. The company currently holds 4 Class III Medical Device Registration Certificates and 17 Class I Medical Device Filings in China, along with 30 CE certifications, 4 US FDA clearances, 4 UK MHRA certifications, and 3 Indonesia NADFC certifications. Rocgene owns 67 patents (41 invention, 12 utility model, 14 design) and 47 software copyrights. To date, Rocgene’s products have been exported to nearly 20 countries worldwide.

In July 2023, Rocgene relocated to its Beijing headquarters, housing a >10,000 m² R&D and operations center with standardized laboratories. Its Xuzhou subsidiary operates a >10,000 m² intelligent manufacturing center with standardized production facilities, including 4 instrument production lines and 3 reagent production lines. The company has obtained ISO 13485 and ISO 9001 quality management system certifications and continuously enhances its quality management capabilities.

With the courage to transcend and ambition to lead, Rocgene strives to become a forward-looking industry pioneer.

Rocgene Product Series